Sean Moran - Jun 14, 2024 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Role
Chief Financial Officer
Signature
/s/Sean Moran
Stock symbol
CRBP
Transactions as of
Jun 14, 2024
Transactions value $
-$630,018
Form type
4
Date filed
6/18/2024, 05:59 PM
Previous filing
Apr 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRBP Common Stock, par value $0.0001 per share Options Exercise $47K +1.57K +3.22% $30.00 50.2K Jun 14, 2024 Direct F1
transaction CRBP Common Stock, par value $0.0001 per share Sale -$78.2K -1.57K -3.12% $49.87 48.6K Jun 14, 2024 Direct F1, F2, F3
transaction CRBP Common Stock, par value $0.0001 per share Options Exercise $33.2K +7.79K +16.02% $4.26 56.4K Jun 14, 2024 Direct F1
transaction CRBP Common Stock, par value $0.0001 per share Sale -$388K -7.79K -13.81% $49.87 48.6K Jun 14, 2024 Direct F1, F2, F3
transaction CRBP Common Stock, par value $0.0001 per share Options Exercise $94.9K +6.73K +13.85% $14.10 55.3K Jun 17, 2024 Direct F1
transaction CRBP Common Stock, par value $0.0001 per share Sale -$315K -6.73K -12.16% $46.77 48.6K Jun 17, 2024 Direct F1, F2, F4
transaction CRBP Common Stock, par value $0.0001 per share Options Exercise $58.7K +1.96K +4.03% $30.00 50.6K Jun 18, 2024 Direct F1
transaction CRBP Common Stock, par value $0.0001 per share Sale -$82.5K -1.96K -3.87% $42.12 48.6K Jun 18, 2024 Direct F1, F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRBP Options to purchase common stock Options Exercise $0 -1.57K -44.45% $0.00 1.96K Jun 14, 2024 Common Stock 1.57K $30.00 Direct F6
transaction CRBP Options to purchase common stock Options Exercise $0 -7.79K -25% $0.00 23.4K Jun 14, 2024 Common Stock 7.79K $4.26 Direct F7
transaction CRBP Options to purchase common stock Options Exercise $0 -6.73K -37.5% $0.00 11.2K Jun 17, 2024 Common Stock 6.73K $14.10 Direct F8
transaction CRBP Options to purchase common stock Options Exercise $0 -1.96K -100% $0.00* 0 Jun 18, 2024 Common Stock 1.96K $30.00 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This amount includes 40,176 restricted stock units ("RSUs"), which vest 25% on each of the first, second, third and fourth anniversary beginning on February 12, 2025.
F2 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.26 to $52.525 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.88 to $49.47 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.10 to $43.59 per share, inclusive. The reporting person undertakes to provide to Corbus Pharmaceuticals Holdings, Inc., any security holder of Corbus Pharmaceuticals Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F6 The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and is fully vested.
F7 The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
F8 The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 1, 2023, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2023.